India, March 18 -- Bio-Path Holdings, Inc. (BPTH) Tuesday reported encouraging results from preclinical studies of BP1001-A that support its potential as a treatment for obesity in patients with Type 2 diabetes.
Updated results from the second stage of pre-clinical studies in skeletal muscle fiber cell models showed that BP1001-A increases insulin sensitivity in C2C12 myotubes. previously Bio-Path had reported that BP1001-A increased insulin sensitivity in myoblast cells.
High fat diet rich in saturated fatty acids can lead to insulin resistance. Palmitic acid, the most common saturated fatty acid in a high fat diet, has been shown to impair insulin signaling. Recent pre-clinical work showed that BP1001-A attenuated palmitic acid-induced ...